27 research outputs found
Hawaii's Marine Fisheries: Some History, Long-term Trends, and Recent Developments
This paper provides an overview of Hawaii's marine fisheries from 1948 to the present. After three decades of decline following a brief period of growth at the conclusion to World War lI, Hawaii's commercial fisheries began a decade of sustained development in the 1980's. At the same time, fisheries management issues became more significant as different segments of the fishery came into more direct competition. This paper provides new estimates of commercial landings for the 1977-90 period, and summarizes limited information on recreational and subsistence fisheries in the 1980's. It also provides some historical context which may be useful in evaluating fishery development and management options
Economics and Hawaii's Marine Fisheries
This paper reviews economic research conducted on Hawaii's marine fisheries over the past ten years. The fisheries development and fisheries management context for this research is also considered. The paper finds that new approaches are required for marine fisheries research in Hawaii: A wider scope to include other marine resource and coastal zone issues, and increased and closer collaboration between researchers and the fishing community
REGIONAL ECONOMIC IMPACTS OF REDUCTIONS IN FISHERIES PRODUCTION: A SUPPLY-DRIVEN APPROACH
Much debate and subsequent confusion have recently been generated regarding the economic importance of the longline fisheries for tuna and swordfish in Hawaii. Depending on the methodology employed, the measures of the economic importance of these fisheries to Hawaii can vary significantly. This paper attempts to provide an assessment of the alternative measures and their implications for fishery policy. In assessing the economic impact of the reduction in longline activities due to season and area closures as mandated by a recent court order, we suggest that the supply-driven approach is more appropriate. An empirical application using the supply-driven approach is used to estimate the economy-wide impacts of a 100% reduction in Hawaii-based longline activities. In addition, a set of supply-driven multipliers is derived for the other sectors of Hawaii's economy to allow comparison with the fishery sectors.Resource /Energy Economics and Policy,
A Bioeconomic Analysis of the Northwestern Hawaiian Islands Lobster Fishery
Several surplus production-based bioeconomic models are applied to the Northwestern Hawaiian Islands (NWHI) commercial lobster fishery. The model which best explains the biological dynamics of the fishery is a modification of the Fox model developed by the authors. Economic costs are applied within a number of conceptual frameworks to develop the first integrated bioeconomic model of the fishery. In another development, the opportunity cost of labor based on crew share at the open access equilibrium level of fishing effort is used instead of proxy wage levels. Given the costs incurred, the fishery appears to be self-regulating in terms of long-term fishing effort for maximum sustainable yield.biological production models, fisheries economics, fisheries management, spiny lobster, slipper lobster, Environmental Economics and Policy, Resource /Energy Economics and Policy,
The role of the integument with respect to different modes of locomotion in the Nematalycidae (Endeostigmata)
Differential responses of the gut transcriptome to plant protein diets in farmed Atlantic salmon
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5âĂâ1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1â-ârelative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23â848 participants were enrolled and 11â636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74â341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Background
A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials.
Methods
This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5âĂâ1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1â-ârelative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674.
Findings
Between April 23 and Nov 4, 2020, 23â848 participants were enrolled and 11â636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0â75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4â97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8â80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74â341 person-months of safety follow-up (median 3·4 months, IQR 1·3â4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation.
Interpretation
ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials
The state as macroeconomic manager in the United States
Typescript.Bibliography: leaves 307-335.Photocopy.Microfilm.x, 335 leaves, bound ill. 29 c
Recommended from our members
National Oceanic and Atmospheric Administration Report 252
The following report was prepared after a series of workshops held by the ad hoc NMFS Limited Access Working Group (LAWG) in the period 1994-97. This report discusses the basics of limited access programs to be developed and implemented in NMFS fisheries, design and scoping considerations, limited access alternatives, nature of the fishing right, coordination and equity, implementation--including eligibility, monitoring, and evaluations, and evaluation